Myra Happe, Amelia R Hofstetter, Jing Wang, Galina V Yamshchikov, LaSonji A Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A Stanley, Aurélie Ploquin, Robert T Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa, Zonghui Hu, Ingelise J Gordon, Nadine Rouphael, Katherine V Houser, Emily E Coates, Barney S Graham, Richard A Koup, John R Mascola, Nancy J Sullivan, Merlin L Robb, Julie A Ake, Kirsten E Lyke, Mark J Mulligan, Julie E Ledgerwood, Hannah Kibuuka
Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG)...
March 29, 2024: NPJ Vaccines